الملخص
This study was done to determine the time while the binary admixtures with midazolam and haloperidol drugs are administered by perfusion to the patients in the clinical routine. Samples with different concentrations of both drugs were prepared following the usual clinical practice. Solvents used were 0.9 % sodium chloride solution and 5% dextrose, and viaflo plastic bags were used as the containers of the admixtures. Samples were not protected from light and were stored at 20 ºC or at 4 ºC. Compatibility and physicochemical stability were studied by visual inspection, turbidity measurement, pH determination and ultraviolet detection high performance liquid chromatography (UV-HPLC) was used to determine midazolam and haloperidol concentrations. The assay was validated following the FDA and EMA guidelines. Darunavir was used as internal standard (IS). For the studied admixtures, turbidity measurements and pH determinations showed little changes in function of the time. Haloperidol and midazolam concentrations determined by HPLC are within the acceptable range of drug concentrations, which are considered stable for four days in case of admixtures stored at 20 ºC and for seven days for refrigerated admixtures. Taking into account the microbiological risk matrix, the compatibility and the chemical and microbiological stability of the midazolam and haloperidol in the co-administered admixtures in viaflo plastic bags with 0.9 % sodium chloride solution and 5% dextrose can be set as 48 hours when samples are stored at 20 ºC and one week if they are refrigerated.
الموضوعات
Midazolam/pharmacology , Haloperidol/pharmacology , Chromatography, High Pressure Liquid/methods , Hypnotics and Sedatives/administration & dosageالملخص
Neuroleptic drugs such as haloperidol has side effects on extrapyramidal pathways. Tardive Dyskinesia is the most important complication. The most characteristic feature of this Tardive Dyskinesia is involuntary movements of mouth and face. In regard to this problem, the induction of gliosis and cell death in the nervous tissue are considered. In this study, adult Sprague-Dawley rats were used as experimental models. Rats were divided into control and experimental groups. The rats were kept in the animal house under standard conditions during experiments. The control rats were intraperitoneally treated with normal saline for 6 days. The experimental samples were treated for the same time with 2, 5 and 10 mg haloperidol. After the trial period, the rats were killed following general anesthesia and their brains were removed after perfusion with a 4 percent formalin solution. Then, 1 mm cuts of the brains were obtained. After that, 5 um tissue sections were prepared and stained with hematoxylin and eosin. The stained sections were examined by optical microscopy. The results showed that the short-term use of haloperidol does not lead to gliosis process in the rat cerebral cortex. The short-term use of 10 mg haloperidol results in cell death in the rat cerebral cortex. Cell death was not observed in the control group and the groups that had received 2 mg and 5 mg doses of haloperidol. According to previous studies, it can be concluded that the gliosis process is induced in the cerebral cortex only following the long-term use of haloperidol. It is considered as a secondary cause of the neuroleptic drugs side effects. The primary cause of these side effects is the induction of cell death in neurons.
Los fármacos neurolépticos como el haloperidol tiene efectos secundarios sobre las vías extrapiramidales. La discinesia tardía es la complicación más importante. El rasgo más característico de esta discinesia tardía son movimientos involuntarios de la boca y cara. En lo que respecta a este problema, se consideran la inducción de gliosis y muerte celular en el tejido nervioso. En este estudio, fueron utilizados ratas Sprague - Dawley adultas como modelos experimentales. Las ratas se dividieron en grupos control y experimentales, y se mantuvieron en condiciones estándar durante los experimentos. Las ratas control fueron tratadas por vía intraperitoneal con solución salina normal durante 6 días, y las experimentales durante el mismo tiempo con 2 , 5 y 10 mg de haloperidol. Luego, las ratas se sacrificaron y sus cerebros se extrajeron después de la perfusión con una solución de formalina al 4 por ciento, obteniendo cortes de 1 mm de los cerebros. Se prepararon y se tiñeron con hematoxilina y eosina en secciones de tejido de 5 micras, y se examinaron por microscopía óptica. Se observó que el uso a corto plazo del haloperidol no conduce a proceso de gliosis en la corteza cerebral de rata. El uso a corto plazo de 10 mg de haloperidol produjo muerte celular en la corteza cerebral de rata. La muerte celular no se observó en el grupo control ni en los grupos que habían recibido 2 y 5 mg de haloperidol. De acuerdo con estudios anteriores, se concluye que el proceso de gliosis se induce en la corteza cerebral sólo tras el uso a largo plazo de exposición al haloperidol. Se considera como una causa secundaria de los efectos adversos de los fármacos neurolépticos. La principal causa de estos efectos secundarios, es la inducción de muerte celular en neuronas.
الموضوعات
Animals , Rats , Cerebral Cortex , Haloperidol/pharmacology , Cell Death , Apoptosis , In Situ Nick-End Labeling , Rats, Sprague-Dawleyالملخص
OBJECTIVES: The aim of our study was to investigate the impact of typical and atypical antipsychotic drugs on leptin concentration in blood and changes in the receptor expression in the hypothalamus of male Wistar rats. METHODS: From the age of 13 to 18 weeks, three groups of 20 animals were fed an average dose of 3.5 + 0.03 mg/ kg body weight (BW) haloperidol; 30.6 + 0.22 mg/kg BW clozapine; or 14.9 + 0.13 mg/kg BW ziprasidone in ground food pellets containing 15 percent fat. Twenty control animals received no drugs. Blood samples were taken at week 14, 16, and 19. Locomotor activity and exploratory behavior were measured using the alcove test at weeks 15 and 17. The expression of the hypothalamic leptin receptor in rat brains was determined by using a Western blot. RESULTS: Rats medicated with haloperidol and ziprasidone showed a significantly decreased percentage weight gain and food consumption. We observed no differences in the alcove test, but locomotor activity was significantly reduced in the haloperidol group. Except for rats in the clozapine and ziprasidone groups, after 2 weeks of drug application, we found no changes in the leptin blood concentrations among the four groups or animals within each group. Moreover, we did not find specific differences in hypothalamic leptin receptor expression among the groups. CONCLUSION: We concluded that in male Wistar rats during this treatment period, the tested drugs did not act directly on the leptin regulatory system. We recommend further studies using long-term treatment of different rat strains.
الموضوعات
Animals , Male , Rats , Antipsychotic Agents/pharmacology , Eating/drug effects , Hypothalamus/chemistry , Leptin/blood , Receptors, Leptin/analysis , Weight Gain/drug effects , Blotting, Western , Clozapine/pharmacology , Exploratory Behavior/drug effects , Haloperidol/pharmacology , Hypothalamus/drug effects , Motor Activity/drug effects , Piperazines/pharmacology , Rats, Wistar , Time Factors , Thiazoles/pharmacologyالملخص
Buspirone, a partial agonist of 5-hydroxytryptamine autoreceptors, selectively blocks presynaptic nigrostriatal D2 dopamine (DA) autoreceptors. At doses which antagonised action of apomorphine in biochemical presynaptic nigrostriatal D2 DA autoreceptor test systems buspirone neither induced catalepsy nor antagonised apomorphine-induced turning behaviour in rats indicating that at these doses buspirone does not block postsynaptic striatal D2 and D1 DA receptors. This study determines whether at high doses buspirone blocks postsynaptic striatal D2 and D1 DA receptors and provides behavioural evidence for selective blockade of presynaptic nigrostriatal D2 DA autoreceptors by smaller doses of buspirone. We investigated in rats whether buspirone induces catalepsy and effect of its pretreatment on DA agonist induced oral stereotypies and on cataleptic effect of haloperidol and small doses (0.05, 0.1 mg/kg, ip) of apomorphine. Buspirone at 1.25, 2.5, 5 mg/kg, ip neither induced catalepsy nor antagonised apomorphine stereotypy but did potentiate dexamphetamine stereotypy and antagonised cataleptic effect of haloperidol and small doses of apomorphine. Buspirone at 10, 20, 40 mg/kg, ip induced catalepsy and antagonised apomorphine and dexamphetamine stereotypies. Our results indicate that buspirone at 1.25, 2.5, 5 mg/kg blocks only presynaptic nigrostriatal D2 DA autoreceptors while at 10, 20, 40 mg/kg, it blocks postsynaptic striatal D2 and D1 DA receptors. Furthermore, buspirone at 1.25, 2.5, 5 mg/kg by selectively blocking presynaptic nigrostriatal D2 DA autoreceptors, increases synthesis of DA and makes more DA available for release by dexamphetamine and during haloperidol-induced compensatory 'feedback' increase of nigrostriatal DAergic neuronal activity and thus potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
الموضوعات
Animals , Apomorphine/pharmacology , Buspirone/pharmacology , Catalepsy/chemically induced , Dextroamphetamine/pharmacology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Rats , Rats, Wistar , Receptors, Dopamine D1/antagonists & inhibitors , Receptors, Dopamine D2/antagonists & inhibitors , Stereotyped Behavior/drug effectsالملخص
Glycogen synthase kinase 3 (GSK3) was recently suggested to be a potential target of psychotropics used in psychiatric illnesses such as schizophrenia and bipolar disorder. Relevant studies have found that antipsychotic drugs regulate GSK3 activity via an increase in either inhibitory serine phosphorylation or amount of GSK3 after acute or subchronic treatment. Recent evidence shows that GSK3 is regulated by dopaminergic or serotonergic systems implicated in the pathophysiology and treatment mechanisms of schizophrenia and bipolar disorder. Therefore, antipsychotics may regulate GSK3 via antagonizing dopaminergic or serotonergic activity. However, the signaling pathway that is involved in GSK3 regulation by dopaminergic or serotonergic systems has not been well established. Haloperidol is a typical antipsychotic with potent dopamine D(2) receptor antagonism. Clozapine is an atypical antipsychotic with potent serotonin 5HT(2) receptor antagonism. We injected rats with haloperidol or clozapine and examined the phosphorylation and amount of GSK3alpha/beta and its well-known upstream regulators Akt and Dvl in the rat frontal cortex by Western blotting. Both haloperidol and clozapine induced Ser21/9 phosphorylation of GSK3GSK3alpha/beta. Haloperidol increased the Ser473 phosphorylation of Akt transiently, whereas clozapine maintained the increase for 1 h. Haloperidol did not affect the phosphorylation and amount of Dvl, whereas clozapine increased both phosphorylation and the amount of Dvl. Our results suggest that GSK3 activity may be regulated by both typical and atypical antipsychotics and that Akt or Dvl, depending on the D(2)- or 5HT(2)- receptor antagonism properties of typical and atypical antipsychotics, mediate the regulation differently.
الموضوعات
Animals , Male , Rats , Adaptor Proteins, Signal Transducing/metabolism , Antipsychotic Agents/pharmacology , Clozapine/pharmacology , Dopamine Antagonists/pharmacology , Frontal Lobe/drug effects , Glycogen Synthase Kinase 3/metabolism , Haloperidol/pharmacology , Phosphoproteins/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Rats, Sprague-Dawley , Serotonin Antagonists/pharmacology , Signal Transductionالملخص
This study aimed to examine the effects of haloperidol and amphetamine on human startle response modulated by emotionally-toned film clips. Sixty participants, in two groups [one receiving haloperidol and the other receiving amphetamine] were tested using electromyography [EMG] to measure eye-blink muscle [orbicular oculi] while different emotions were induced by six 2-minute film clips. An, affective rating shows the negative and positive effects of the two drugs on emotional reactivity, neither amphetamine nor haloperidol had any impact on the modulation of the startle response. The methodological and theoretical aspects of the study and findings will be discussed
الموضوعات
Humans , Male , Dextroamphetamine/pharmacology , Haloperidol/pharmacology , Psychoacoustics , Electromyography , Blinking , Emotionsالملخص
Ginkgo biloba extract EGb 761 has been reported to have therapeutic effects which have been attributed to anti-oxidant and free radical-scavenging activities, including a direct action on nitric oxide production. L G-nitro-arginine (L-NOARG), a nitric oxide synthase inhibitor, and haloperidol, a drug that blocks dopamine receptors, are both known to induce catalepsy in rodents. Nitric oxide has been shown to influence dopaminergic transmission in the striatum. The purpose of the present study was to evaluate the effect of the extract obtained from leaves of Ginkgo biloba tree EGb 761 on catalepsy induced by haloperidol or by L-NOARG. Albino Swiss mice (35-45 g, N = 8-12) received by gavage a single or repeated oral dose (twice a day for 4 days) of EGb 761 followed by ip injection of haloperidol or L-NOARG. After the treatments, the animals were submitted to behavioral evaluation using the catalepsy test. Acute treatment with 80 mg/kg EGb did not modify the catalepsy induced by L-NOARG but, the dose of 40 mg/kg significantly enhanced haloperidol-induced catalepsy measured at the 10th min of the test. After repeated treatment with 80 mg/kg EGb 761, a significant increase in the cataleptic effect produced by both haloperidol and L-NOARG was observed. These data show that repeated EGb 761 administration increases the effects of drugs that modify motor behavior in mice. Since the catalepsy test has predictive value regarding extrapyramidal effects, the possibility of pharmacological interactions between haloperidol and Ginkgo biloba extracts should be further investigated in clinical studies.
الموضوعات
Animals , Male , Mice , Dopamine Antagonists/pharmacology , Catalepsy/chemically induced , Plant Extracts/pharmacology , Haloperidol/pharmacology , Enzyme Inhibitors/pharmacology , Nitroarginine/pharmacology , Drug Interactions , Ginkgo biloba , Time Factorsالملخص
5-hydroxytryptamine (5-HT) inhibits the synthesis and release of dopamine (DA) from rat nigrostriatal DAergic neurons. Dexfenfluramine releases 5-HT from brain 5-HTergic neurons. The present study was undertaken to determine whether dexfenfluramine, through the released 5-HT, modulates the intensity of the behaviours dependent on the functional status of the nigrostriatal DAergic system. The effect of pretreatment with dexfenfluramine on dexamphetamine and apomorphine stereotypies of the oral movement variety and on catalepsy induced by haloperidol and small doses (0.05 and 0.1 mg/kg ip) of apomorphine was studied in rats. We also investigated whether dexfenfluramine induces catalepsy in rats. Dexfenfluramine at 2.5, 5 and 10 mg/kg ip did not induce catalepsy and did not antagonise apomorphine stereotypy. However, 1 h pretreatment with 5-HT releasing doses of dexfenfluramine ie 5 and 10 mg/kg ip, antagonized dexamphetamine stereotypy and potentiated catalepsy induced by haloperidol and small doses of apomorphine. Our results, that dexfenfluramine at 2.5, 5 and 10 mg/kg ip neither induced catalepsy nor antagonised apomorphine stereotypy, indicate that dexfenfluramine at these doses does not block the postsynaptic striatal D2 and D1 DA receptors. They also indicate that the 5-HT released by 5 and 10 mg/kg dexfenfluramine does not exert an inhibitory effect at or beyond the postsynaptic striatal D2 and D1 DA receptor sites. However, 5 and 10 mg/kg doses of dexfenfluramine, through the released 5-HT, inhibit the synthesis and release of DA from the nigrostriatal DAergic neurons and thus antagonise dexamphetamine stereotypy and potentiate catalepsy induced by haloperidol and small doses of apomorphine.
الموضوعات
Animals , Dexfenfluramine/pharmacology , Dopamine/metabolism , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Rats , Rats, Wistar , Stereotyped Behavior/drug effectsالملخص
In the present study, half of the pups of a litter were undernourished by 12 h daily maternal deprivation from day 5 to day 18 postnatal and were subsequently nutritionally rehabilitated. Responses of CNS-acting drugs (morphine analgesia, pentobarbitone sodium hypnosis, haloperidol catalepsy) were studied at the age of day 9, 12 and 18 in maternally deprived and of day 25 in nutritionally rehabilitated new born rats as compared to that of their nourished littermates. The results showed that the response of these CNS-acting drugs was maximum at the age of day 9 postnatal and progressively decreased thereafter as the age of the animal advanced. The responses of these drugs in maternally deprived animals varied on different days of undernourishment as compared to that of their nourished littermates. The responses were significantly less in first half and were significantly more in second half period of undernourishment. The changes observed in the responses of these CNS-acting drugs were directly related to the changes observed in brain serotonin level in maternally deprived and nutritionally rehabilitated new born rats. The present findings suggest that the nature and degree of undernutrition imposed in suckling rats might only produce temporary effects on the response of CNS-actin drugs and on brain serotonin levels which is reversible if undernourished new born rats were nutritionally rehabilitated on an appropriate time of brain development.
الموضوعات
Analgesia , Analgesics, Opioid/pharmacology , Animals , Animals, Newborn , Behavior, Animal/drug effects , Catalepsy/chemically induced , Central Nervous System Agents/pharmacology , Drug Tolerance , Female , Haloperidol/pharmacology , Morphine/pharmacology , Nutrition Disorders , Phenobarbital/pharmacology , Rats , Rats, Inbred F344الملخص
Effect of active tannoid principles of E. officinalis, comprising of emblicanin A (37%), emblicanin B (33%), punigluconin (12%) and pedunculagin (14%), was investigated on a rat model of tardive dyskinesia (TD) induced by once daily administration of haloperidol (1.5 mg/kg, ip) for 28 days. Involuntary orofacial movements (chewing movements, buccal tremors and tongue protusion) were assessed as TD parameters. The tannoid principles of E. officinalis (EOT) were administered concomitantly with haloperidol in the doses of 10, 20 and 50 mg/kg, po, for 28 days. Sodium valproate (200 mg/kg, po), a Gaba-mimetic agent, and vitamin E (400 mg/kg, po), an antioxidant, were used as the standard drugs and administered for the same period. EOT induced a dose-related inhibition of all the three TD parameters assessed, as did vitamin E. The effect of sodium valproate remained statistically insignificant. The results suggest that EOT exerts a prophylactive effect against neuroleptic-induced TD which is likely to be due to its earlier reported antioxidant effects in rat brain areas, including striatum.
الموضوعات
Animals , Anti-Dyskinesia Agents/pharmacology , Anticonvulsants/pharmacology , Antioxidants/pharmacology , Brain/drug effects , Disease Models, Animal , Dyskinesia, Drug-Induced/prevention & control , Euphorbiaceae/chemistry , GABA Modulators/pharmacology , Haloperidol/pharmacology , Male , Phytotherapy , Plant Extracts/chemistry , Plant Roots/chemistry , Rats , Rats, Wistar , Tannins/pharmacology , Valproic Acid/pharmacology , Vitamin E/pharmacologyالملخص
The widespread consumption of anorectics and combined anorectic + alcohol misuse are problems in Brazil. In order to better understand the interactive effects of ethanol (EtOH) and diethylpropion (DEP) we examined the locomotion-activating effects of these drugs given alone or in combination in mice. We also determined whether this response was affected by dopamine (DA) or opioid receptor antagonists. A total of 160 male Swiss mice weighing approximately 30 g were divided into groups of 8 animals per group. The animals were treated daily for 7 consecutive days with combined EtOH + DEP (1.2 g/kg and 5.0 mg/kg, ip), EtOH (1.2 g/kg, ip), DEP (5.0 mg/kg, ip) or the control solution coadministered with the DA antagonist haloperidol (HAL, 0.075 mg/kg, ip), the opioid antagonist naloxone (NAL, 1.0 mg/kg, ip), or vehicle. On days 1, 7 and 10 after the injections, mice were assessed in activity cages at different times (15, 30, 45 and 60 min) for 5 min. The acute combination of EtOH plus DEP induced a significantly higher increase in locomotor activity (day 1: 369.5 + or - 34.41) when compared to either drug alone (day 1: EtOH = 232.5 + or - 23.79 and DEP = 276.0 + or - 12.85) and to control solution (day 1: 153.12 + or - 7.64). However, the repeated administration of EtOH (day 7: 314.63 + or - 26.79 and day 10: 257.62 + or - 29.91) or DEP (day 7: 309.5 + or - 31.65 and day 10: 321.12 + or - 39.24) alone or in combination (day 7: 459.75 + or - 41.28 and day 10: 427.87 + or - 33.0) failed to induce a progressive increase in the locomotor response. These data demonstrate greater locomotion-activating effects of the EtOH + DEP combination, probably involving DA and/or opioid receptor stimulation, since the daily pretreatment with HAL (day 1: EtOH + DEP = 395.62 + or - 11.92 and EtOH + DEP + HAL = 371.5 + or - 6.76; day 7: EtOH + DEP = 502.5 + or - 42.27 and EtOH + DEP + HAL = 281.12 + or - 16.08; day 10: EtOH + DEP = 445.75 + or - 16.64 and EtOH + DEP + HAL = 376.75 + or - 16.4) and NAL (day 1: EtOH + DEP = 553.62 + or - 38.15 and EtOH + DEP + NAL = 445.12 + or - 55.67; day 7: EtOH + DEP = 617.5 + or - 38.89 and EtOH + DEP + NAL = 418.25 + or - 61.18; day 10: EtOH + DEP = 541.37 + or - 32.86 and EtOH + DEP + NAL = 427.12 + or - 51.6) reduced the locomotor response induced by combined administration of EtOH + DEP. These findings also suggest that a major determinant of combined anorectic-alcohol misuse may be the increased stimulating effects produced...
الموضوعات
Animals , Male , Mice , Appetite Depressants/pharmacology , Diethylpropion/pharmacology , Dopamine Antagonists/pharmacology , Ethanol/pharmacology , Motor Activity/drug effects , Receptors, Opioid/antagonists & inhibitors , Haloperidol/pharmacology , Naloxone/pharmacology , Narcotic Antagonists/pharmacologyالملخص
The aim of the present study was to evaluate the effect of antidopaminergic agents on the somatotrophs in the presence of hyperprolactinemia. Adult male Wistar rats were divided into 6 groups: a control group and five groups chronically treated (60 days) with haloperidol, fluphenazine, sulpiride, metoclopramide or estrogen. Somatotrophs and lactotrophs were identified by immunohistochemistry and the data are reported as percent of total anterior pituitary cells counted. The drugs significantly increased the percentage of lactotrophs: control (mean + or - SD) 21.3 + or - 4.4, haloperidol 27.8 + or - 2.2, fluphenazine 34.5 + or - 3.6, sulpiride 32.7 + or - 3.5, metoclopramide 33.4 + or - 5.5 and estrogen 42.4 + or - 2.8. A significant reduction in somatotrophs was observed in animals treated with haloperidol (23.1 + or - 3.0), fluphenazine (22.1 + or - 1.1) and metoclopramide (24.2 + or - 3.0) compared to control (27.3 + or - 3.8), whereas no difference was observed in the groups treated with sulpiride (25.0 + or - 2.2) and estrogen (27.1 + or - 2.8). In the groups in which a reduction occurred, this may have simply been due to dilution, secondary to lactotroph hyperplasia. In view of the duplication of the percentage of prolactin-secreting cells, when estrogen was applied, the absence of a reduction in the percent of somatotrophs suggests a replication effect on this cell population. These data provide additional information about the direct or indirect effect of drugs which, in addition to interfering with the dopaminergic system, may act on other pituitary cells as well as on the lactotrophs.
الموضوعات
Animals , Male , Rats , Dopamine Antagonists/pharmacology , Estrogens/pharmacology , Growth Hormone/drug effects , Hyperprolactinemia/metabolism , Prolactin/drug effects , Fluphenazine/pharmacology , Growth Hormone/analysis , Haloperidol/pharmacology , Metoclopramide/pharmacology , Prolactin/analysis , Rats, Wistar , Sulpiride/pharmacologyالملخص
Although recently developed drugs have brought significant improvement, the treatment of psychotic disorders still presents serious drawbacks. Since inherent complexity and lack of satisfactory understanding of the underlying pathophysiology impose limits for rational drug design, resourceful approaches in the search for antipsychotics are pertinent. This paper reports pharmacological properties of alstonine, a heteroyohimbine type alkaloid, Which exbitited an antipsychotic-like profile, inhibiting amphetamine-induced lethaly, apomorphine-induced steotypy and potentiating barbiturate-induced slleping time. Atypical features of alstonine were the prevention of haloperidol-induced catalepsy and lack of direct interaction with D1, D2 and 5-HT2A receptors, classically linked to antipsychotic mechanism of action.
الموضوعات
Animals , Male , Mice , Antipsychotic Agents/pharmacology , Plants, Medicinal , Secologanin Tryptamine Alkaloids/pharmacology , Amphetamine/antagonists & inhibitors , Apomorphine/antagonists & inhibitors , Barbiturates/antagonists & inhibitors , Central Nervous System Stimulants/antagonists & inhibitors , Chlorpromazine/pharmacology , Clozapine/pharmacology , Diazepam/pharmacology , Emetics/antagonists & inhibitors , Haloperidol/pharmacology , Hypnotics and Sedatives/antagonists & inhibitors , Nigeria , Pentobarbital/pharmacology , Reserpine/pharmacology , Sleep/drug effects , Stereotyping , Sulpiride/pharmacologyالملخص
Different groups of pregnant rats were treated with diazepam (10 mg/kg), phenobarbital (10 mg/kg), haloperidol (0.1 mg/kg), fluoxetine (10 mg/kg) and vehicle (normal saline) intraperitoneally once a day during gestation days 13 to 21. After birth these pups were culled to 8 pups/dam and foster-nursed by lactating mothers for 3 weeks and were reared in colony cages thereafter. Sex and weight matched pairs of rat offsprings were subjected to foot shock induced aggression test at 8 weeks of age. Two parameters of aggressive behaviour were recorded namely, the latency to fight and total number of fighting bouts. The results indicate that prenatal exposure to diazepam, phenobarbital, haloperidol and fluoxetine caused significantly enhanced aggression in terms of number of fighting bouts.
الموضوعات
Aggression , Animals , Diazepam/pharmacology , Drug Evaluation, Preclinical , Electroshock , Female , Fluoxetine/pharmacology , Haloperidol/pharmacology , Phenobarbital/pharmacology , Pregnancy , Prenatal Exposure Delayed Effects , Psychotropic Drugs/pharmacology , Ratsالملخص
Effect of clozapine on MK-801-induced hyperlocomotion and stereotypy as well as open field behavior was studied. Clozapine (0.1-7.5 mg/kg) dose-dependently blocked MK-801(0.5 mg/kg)-induced stereotypy. Both total and ambulatory responses were blocked by even the lower doses (0.1-0.5 mg/kg) of clozapine. In open field test, clozapine selectively blocked hyperambulation induced by MK-801 (0.1 mg/kg) whereas it potentiated MK-801 (0.1 mg/kg)-induced stereotypy at all the doses used. Haloperidol (0.25 and 0.5 mg/kg) and SCH 23390 (0.5 and 1 mg/kg) showed a dose-dependent effect on MK-801-induced behaviors while sulpiride (25 and 50 mg/kg) failed to modify MK-801-induced open field behavior. This study supports the preferential effect of clozapine on dopamine receptors located in mesolimbic area and further suggests the possibility of using open field behavior induced by MK-801 as a model for studying atypical antipsychotics.
الموضوعات
Analysis of Variance , Animals , Antipsychotic Agents/pharmacology , Benzazepines/pharmacology , Clozapine/pharmacology , Dizocilpine Maleate/antagonists & inhibitors , Dose-Response Relationship, Drug , Drug Interactions , Haloperidol/pharmacology , Hyperkinesis/chemically induced , Mice , Mice, Inbred BALB C , N-Methylaspartate/antagonists & inhibitors , Neuroprotective Agents/pharmacology , Rats , Rats, Wistar , Stereotyped Behavior/drug effects , Sulpiride/pharmacologyالملخص
Incidence of severe depression is very common in Parkinson's disease (PD). Use of antidepressants in such cases is known to improve or worsen the existing PD. However, prediction of the effect of antidepressant on symptoms of PD is limited due to lack of suitable animal model. The present study examines the possibility of using haloperidol-induced catalepsy model in rats for this purpose. Antidepressants showed distinct effect on haloperidol-induced catalepsy, although most of them reduced forced-swimming induced immobility. In general, antidepressants with greater noradrenergic reuptake inhibition (desipramine, imipramine, amitriptyline, nortriptyline, protriptyline and maprotiline) reduced, whereas those with serotonergic reuptake inhibition (fluoxetine and clomipramine) increased haloperidol-induced catalepsy. Mianserin, an atypical antidepressant, and alprazolam, a benzodiazepine receptor analogue had no effect on haloperidol-induced catalepsy. The results suggest that haloperidol-induced catalepsy model in rats needs to be incorporated in the screening procedure when evaluating the utility of antidepressant drugs for the treatment of depression associated with PD.
الموضوعات
Animals , Antidepressive Agents/therapeutic use , Catalepsy/chemically induced , Depressive Disorder/complications , Drug Evaluation, Preclinical , Haloperidol/pharmacology , Male , Parkinson Disease/complications , Ratsالملخص
The study involved exploration of the role of dopamine antagonist haloperidol on the testicular functions of rat. Chronic administration of haloperidol (0.2 mg/kg/day/sc for 21 days) caused significant increase in brain DA and serum prolactin. At testicular level the treatment revealed atrophic degeneration of seminiferous epithelium indicating suppression of hypophyseal gonadotrophins and proves importance of dopaminergic control over prolactin release for normal functions of male gonad.
الموضوعات
Animals , Dopamine Antagonists/pharmacology , Haloperidol/pharmacology , Male , Rats , Rats, Sprague-Dawley , Testis/drug effectsالملخص
It is necessary to use experimental animals with behavioural, physiological and disease susceptibility pattern similar to man so that the results have a clinical predictive value. For such studies the non-human primate is the animal of choice. Rhesus monkey is a good choice for this purpose but information about its behaviour is fragmentary. In order to obtain a quantitative baseline data for psychopharmacological studies, a protocol has been developed to score various social and solitary behaviours in adult male and female rhesus monkeys. The study was conducted on rhesus monkeys in a social colony of one male and seven female living in a semi-restricted environment. The behavioural patterns were quantitated so as to compare effect on various components of behaviour. Aggressiveness and vigilance were prominent in the male while social affiliative behaviour was dominant in the female. Other behavioural responses were of similar magnitude in both sexes. It is however necessary to have data with some standard CNS active agents on these behavioural protocol. Therefore, initially the behavioural effects of amphetamine and haloperidol were studied. Significant effects observed following d-amphetamine (1-4 mg/kg, im); it induced dose dependent suppression of social behaviour (approach, contact, grooming), feeding, hypervigilance, stereotypy and oral hyperkinesia. On the other hand haloperidol (0.01-0.04 mg/kg, im) produced decrease in social and solitary behaviour and marked cataleptic posture. It is possible to quantitate drug effects on various aspects of behaviour of the rhesus monkey and to develop neuropsychitric models with the help of this protocol for use in study of drug effects on behaviour.
الموضوعات
Aggression/drug effects , Amphetamine/pharmacology , Animals , Central Nervous System Stimulants/pharmacology , Dopamine Antagonists/pharmacology , Feeding Behavior/drug effects , Female , Grooming/drug effects , Haloperidol/pharmacology , Macaca mulatta , Male , Motor Activity/drug effects , Social Behaviorالملخص
El estudio fue realizado en 80 pacientes ambulatorios del Servicio de Psiquiatría del Hospital Salvador (Santiago, Chile) con diagnóstico de esquizofrenia crónica según los criterios del DSM-IV. 40 pacientes fueron tratados con decanoato de flupentixol (como monoterapia neuroléptica). Los 40 restantes (grupo control) fueron tratados con uno o más de los siguientes neurolépticos: clorpromazina, haloperidol, tioridazina, decanoato de flufenazina. Ambos grupos fueron evaluados en entrevistas psiquiátricas y psicológicas utilizando 7 escalas estandarizadas. El uso de decanoato de flupentixol redujo los síntomas positivos y negativos que caracterizan a la esquizofrenia, corroborado por escalas BPRS y CGI.La adhesión al tratamiento con decanoato de flupentixol fue mejor y los efectos colaterales fueron escasos. El grupo control requirió el uso de uno o más neurolépticos para lograr la estabilización o reducción de los síntomas, con la consecuente presentación de efectos colaterales en un mayor número de casos. Finalmente, los resultados positivos obtenidos con decanoato de flupentixol están relacionados con la intensidad de la sintomatología. La efectividad de la medicación fue interior en los pacientes que desarrollaron crisis psicóticas y/o en los pacientes resistentes al tratamiento neuroléptico
الموضوعات
Humans , Male , Female , Adult , Adolescent , Middle Aged , Antipsychotic Agents/classification , Flupenthixol/pharmacology , Schizophrenia/drug therapy , Case-Control Studies , Chlorpromazine/pharmacology , Flupenthixol , Flupenthixol/adverse effects , Haloperidol/pharmacology , Outpatients , Prospective Studies , Rebound Effect , Thioridazine/pharmacologyالملخص
As severall side effects of neuroleptics would be related to their interactions with several neurotransmitter receptors (R) haloperidol action on muscarinic cholinergic (mACh) R on frontal cerebral cortex preparations was analyzed. Here we shown that haloperidol was able to inhibit in a concentration dependent manner the binding of specific mAChR radiollabeled antagonist on cerebral cortex membranes. This effect would be related to its interaction on mAChR of the M1 subtype as haloperidol blocked the stimulation of phosphoiinositides (Pis) turnover induced by low concentrations of carbachol similarly as the M1 antagonist pirenzepine. However at high carbachol concentrations haloperidol triggered a potentiating stimulation of Pis hydrolysis that was only blocked by the alpha1 adrenergic antagonist prazosin indicating and alpha1 agonistic action of haloperidol on these Rs. These multireceptor actions of haloperidol found "in vitro"would strengthen its assocation with "in vivo"neuroleptic-induced side effects.